HPMC phthalate

In the present research study focuses on formulate and evaluate Polymeric Microparticles of Eprosartan Mesylate aiming to increase the therapeutic efficacy, reduce the frequency of administration and to improve the patient compliance. Controlled release polymeric microparticles of Eprosartan Mesylate, were formulate by using different drug polymer ratios HPMC Phthalate and Eudragit S 100. The various formulations of controlled release Polymeric Microparticles of Eprosartan Mesylate were formulated by using various concentrations of different polymers HPMC Phthalate and Eudragit S 100 by fusion method. The Polymeric Microparticles were evaluated for pre compression and post compression parameters (Angle of repose, Tapped density & Percentage compressibility index) and In-vitro dissolution. The results indicated that the, physical parameters of microparticles were within the Pharmacopeial specifications. Among the different formulation, F4 showed controlled release of drug for 24 hours with 80.27% release. The kinetic drug release, the data was treated according to different model. The drug release data of F1-F5 fitted to Higuchi plots were best fit into Higuchi equation and diffusion mechanism. The result shows that, drug release rate for the F4 formulation follow the zero order mechanism. The selected formulation (F4) was subjected to stability studies for three months at 25°C/60% RH, 30°C/65% RH and 40°C/75% RH and showed stability with respect to release pattern and all physical parameters. Thus, drug in Polymeric Microparticles with Eudragit S 100 were found to be effective in retarding the release of Eprosartan Mesylate.

The present study focuses on developing sustained release matrix tablets of Ibrutinib aiming to increase the therapeutic efficacy, reduce the frequency of administration and to improve the patient compliance. Sustained release matrix tablets of Ibrutinib, were developed by using different drug polymer ratios HPMC phthalate, Eudragit L 100, Eudragit S 100 as matrix former. All lubricated formulations were compressed by direct compression and by wet granulation method. Compressed tablets were evaluated for uniformity of weight, content of active ingredient, friability, hardness, thickness, in-vitro dissolution, and swelling index. All the formulation showed compliance with pharmacopoeial standards. Among the different formulation, B8 showed sustained release of drug for 12 hours with 86.55% release. The selected formulation (B8) was subjected to stability studies for three months at 25°C/60% RH, 30°C/65% RH and 40°C/75% RH and showed stability with respect to release pattern and all physical parameters. The regression coefficient value of Higuchi plot was found to be 0.9925 that showed that drug was released by diffusion mechanism. The slope value of korsmeyer-peppas equation was found to be 0.5062 which indicating that drug was released by non-fickian release mechanism. The R2 value for Hixson Crowell plot was found to be 0.9919 which indicates that drug release was limited by drug particle dissolution rate and erosion of the polymer matrix. Thus, drug in combination with Eudragit S 100 were found to be effective in retarding the release of Ibrutinib.